Abstract
Plasmacytoid dendritic cells (pDCs) express TLR7, a ssRNA-sensor encoded on the X chromosome, which escapes X chromosome inactivation (XCI) in females. pDCs are specialized in the production of type 1 interferons (IFN-I) through TLR7 activation which mediates both immune cell activation and also reactivation of latent HIV-1. The effect of HIV-1 infection in women under antiretroviral therapy (ART) on pDC functional responses remains poorly understood. Here, we show that pDCs from HIV/ART women exhibit exacerbated production of IFN-α and TNF-α as compared to uninfected controls (UC) upon TLR7-activation. Because TLR7 can escape XCI in female pDCs, we measured the contribution of TLR7 allelic expression using SNP haplotypic markers to rigorously tag the allele of origin of TLR7 gene at single cell resolution. Herein, we provide evidence that the functional reprogramming of pDCs in HIV/ART women is associated with enhanced transcriptional activity of the TLR7 locus from both X chromosomes, rather than differences in the frequency of TLR7 bi-allelic cells. These data reinforce the interest in targeting the HIV-1 reservoir using TLR7 agonists in women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS, EP-53 study), and SIDACTION (Grant 2018-1-AEQ-12035). PA and AY were supported by fellowships from SIDACTION. AY was also supported by PhD fellowships from the CSL Behring Research Funds, Fondation des Treilles and from the Association de la Charite des jeunes de Kafarsir (Liban).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ANRS EP53X_Libris protocol and the informed consent form were submitted and approved by the local ethic committee (Comite de protection des personnes Sud-Ouest et Outre-mer I, ID-RCB: 2013-A00954-1; ANSM: 130876B-41).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: the authors have declared that no conflict of interest exists.
Data Availability
All data produced in the present work are contained in the manuscript
List of abbreviations
- HIV-1
- Human Immunodeficiency Virus-1
- HIV-1/ART
- HIV-1-infected female under antiretroviral therapy
- TLR7
- Toll-like receptor 7
- pDCs
- plasmacytoid dendritic cells
- UC
- uninfected controls
- XCI
- X chromosome inactivation
- Xa
- active X chromosome
- Xi
- inactive X chromosome